In the last decade, strategic partnerships have powered TMC Innovation’s ability to bring together the right resources at the right time—for the right innovators. As the community has grown from concept to global stage, so too has the importance of thoughtful collaboration.
From CPRIT to BioBridge, and from early international agreements to today’s dynamic institutional engagements, partnerships have always been a cornerstone of the TMC Innovation model. Today, they remain essential as we enter a new era—one defined by deeper integration, greater flexibility, and broader opportunities for entrepreneurs, clinicians, and researchers alike.
From Legacy Models to Flexible Support
The launch of JLABS@TMC in 2014 marked a pivotal moment in Houston’s rise as a global life science hub. The presence of Johnson & Johnson signaled that the city was ready to support—and scale—early-stage innovation. Over the past decade, the JLABS model fueled momentum and drew talent from across the world.
Today, with the transition to Innovation Labs @ TMC, we enter a new chapter—one that builds on this momentum while offering greater freedom to support startups beyond any single corporate roadmap. The new model gives TMC the ability to create a more inclusive and responsive innovation environment, with seamless integration across the Innovation Factory, Center for Device Innovation (CDI), and TMC Venture Fund. It also opens the door for more international companies to engage through the BioBridge program, which continues to thrive with partners like Enterprise Ireland, Innovate UK, and BII.
Baylor College of Medicine: From Discovery to Commercialization
TMC Innovation’s partnership with Baylor College of Medicine (BCM) has grown steadily over the past decade, beginning when Baylor Genetics became the first commercial tenant in the Innovation Factory. What started as a diagnostic laboratory spinout has since evolved into a robust model of collaboration that helps translate Baylor’s scientific and clinical strengths into market-ready ventures.
Together, Texas Medical Center and Baylor College of Medicine have spun out companies such as March BioSciences, a portfolio company that has advanced into Phase 2 clinical trials, and Aspira Medical, a collaboration between Dr. Todd Rosengart, Professor and Chair of the Department of Surgery at BCM, and Zaffer Syed, Entrepreneur-in-Residence at TMC Innovation. Programs like the Accelerator for Cancer Therapeutics and the Biodesign fellowship have given Baylor researchers and clinicians structured pathways to commercialize their work, while drawing on TMC’s infrastructure, executive talent, and investment networks to accelerate progress.
“Our scientists are constantly generating discoveries, but no single institution is built to take those ideas all the way to market. Partnering with TMC Innovation gives us the ability to do that at scale. Together, we’ve created companies like March Biosciences and Aspira Medical, examples of what happens when you match Baylor’s research depth with TMC’s commercialization engine,” shares Joe Petrosino, Ph.D., Molecular Virology and Microbiology, Baylor College of Medicine
That alignment has become especially important as Houston’s capacity for life science commercialization has expanded. With the addition of wet bench space, accelerators, and the TMC Venture Fund, Houston now offers the full spectrum of resources needed to turn science into startups.
“In 25 years of working in technology management, I’ve never seen the kind of progress that Houston has made in the last decade. The addition of wet bench capacity, accelerators, and the TMC Venture Fund has created the full set of ingredients needed to build successful companies. What we needed most was executive talent, and through TMC’s programs and Entrepreneur-in-Residence’s, that’s exactly what we’ve been able to provide for our teams,” shares Michael B. Dilling, Ph.D., CLP – Executive Director, Technology Management & Commercialization, Baylor College of Medicine
Portal Innovations: Choosing Houston as the Next Hub
When Chicago-based Portal Innovations began evaluating expansion markets, Houston quickly rose to the top of the list. Strong academic institutions, a rapidly growing clinical research base, and the opportunity to partner with the Texas Medical Center all pointed to a city ready to support the next generation of life science startups.
Portal established its Houston presence within TMC’s Helix Park, bringing investment capital, co-working lab space, and a new fellowship program that draws PhD and MD students into venture development. The firm has already co-invested with TMC Venture Fund in companies like March Biosciences and CrossBridge Bio, underscoring the alignment between the two organizations.
Portal’s commitment goes beyond venture—it extends to community. From hosting high school students in the BioPath program to providing lab space and panel discussions, Portal is helping cultivate the future talent pipeline for Houston’s biomanufacturing sector.
“When we were deciding where to expand, Houston stood out not only for its science and institutions, but for the partnerships we could build here. TMC made what could have been a daunting entry into a huge market feel collaborative and connected. By aligning our venture model with TMC’s accelerators and commercialization pathways, we’re able to support companies for the long term—and invest in the community that will sustain them,” says Monique Knighten – Executive Director, Portal Innovations Houston
A Model Built on Responsiveness
What sets the TMC Innovation collective apart isn’t just infrastructure—it’s the ability to evolve with the needs of our partners. From hands-on prototyping for device companies to early-stage clinical validation and regulatory insight for health tech startups, our tailored approach ensures that each institution and innovator receives the right support at the right stage.
This approach is evident in our new membership model with Memorial Hermann, launched in July 2025. Developed in collaboration with Jason Sakamoto, Associate Director of CDI and Head of Biodesign, the partnership introduces two complementary pathways:
- Clinician Pathway: Nurses, educators, and care providers can bring forward new ideas, with opportunities for prototyping and mentorship at CDI.
- Innovation Track: Operational leaders, analysts, and pharmacists gain exposure to expert advisors in regulatory, product development, and commercialization—preparing them to translate internal concepts into viable technologies.
This partnership is more than a program—it’s a signal. A signal that anyone with proximity to the patient can be part of the innovation process.
Looking Ahead: Partnerships with Purpose
Strategic partnerships have always been a means to an end—not an end in themselves. What matters most is how they translate into impact: for entrepreneurs, for clinicians, and ultimately, for patients.
That same mindset is guiding our upcoming partnership with Baylor College of Medicine’s residency programs, which will add entrepreneurial exposure for fellows and create new pathways for company formation. It’s also reflected in our collaboration with investment partners like Portal Innovations, who share our long-term vision for building a sustainable life science cluster in Houston.
Ten years in, TMC Innovation remains committed to fostering a community where partnerships are not just appreciated—they’re activated. And in this next chapter, that means building on what works, deepening alignment with our partners, and continuing to serve as a trusted guide in the journey from idea to impact.